Skip to content
    DRIO
    Earnings call· Jun 2026(Q2 FY26)

    DarioHealth Q2 FY26 earnings call DRIO

    Aug 11, 2026 Source

    Executive summary

    DarioHealth Q2 FY26 — Multi-Condition Platform and AI Drive Future Growth

    DarioHealth is leveraging its mature multi-condition digital health platform, enhanced by AI capabilities and channel partnerships, to drive compounding growth. The company is strategically shifting towards higher-quality B2B2C recurring revenue, which has temporarily impacted top-line figures but improved profitability metrics. With a strengthened balance sheet and significant contracted ARR, DarioHealth is positioned for accelerated revenue conversion in late 2026 and 2027, focusing on operating leverage and a path to cash flow positivity.

    Highlights

    5

    • Gross margin increased to 62% in Q2 FY26, up from 55% a year ago.

    • Operating expenses reduced by 21% year-over-year in Q2 FY26.

    • Net loss improved by 39% year-over-year to $7.9 million in Q2 FY26.

    • Pro forma cash position strengthened to $36.8 million as of June 2026.

    • Contracted and late-stage annual recurring revenue (ARR) reached $13.1 million, with over 80% multi-condition.

    Concerns

    1

    • Revenue for Q2 FY26 was $5.2 million, a sequential decline from $5.6 million in Q1 FY26 and a year-over-year decline from $5.4 million in Q2 FY25, due to strategic transition away from pharmaceutical services revenue.

    Guidance & targets

    4
    CategoryTargetConfidence
    Contracted Annual Recurring Revenue (ARR) conversion
    $13.1 million
    high materiality
    High
    Recurring Revenue Increase from DarioIQ
    10% to 15% increase
    medium materiality
    High
    New Program Revenue Contribution (Warrior Woman, Carrier Sleep)
    Begin contributing revenue
    medium materiality
    High
    Cash Flow
    Cash flow positive
    high materiality
    High

    Operational metrics

    13
    Contracted Annual Recurring Revenue (ARR)
    $13.1M
    Q2 FY26

    Contracted and late-stage annual recurring revenue at the end of Q2 FY26.

    Recurring Revenue Increase from DarioIQ
    10-15%
    over time

    Expected increase from existing customers due to higher engagement, utilization, and overall customer value.

    Net Loss
    $7.9M39% improvement year-over-year
    Q2 FY26

    Compared to $13M in Q2 FY25.

    Pro Forma Cash Position
    $36.8M
    as of June 2026

    Includes cash, cash equivalents, short-term deposits at quarter-end plus net proceeds from July direct financing.

    Cash, Cash Equivalents, Short-Term Deposits
    $14M
    end of Q2 FY26

    Balance at the end of the second quarter.

    Net Proceeds from Direct Financing
    $22.8M
    July 2026

    Net of offering expenses, closed in July 2026.

    New Accounts from Channel Partners
    approximately 75%
    Q2 FY26

    Represents a structural shift in the commercial model, leading to lower customer acquisition costs and broader reach.

    Fortune 50 Clients
    5
    Q2 FY26

    Includes a newly signed Fortune 50 employer covering over 100,000 eligible employees.

    Fortune 500 B2B2C Client Base
    approximately 25%
    Q2 FY26

    Percentage of B2B2C client base drawn from Fortune 500 companies.

    Proprietary Data Points
    13 billion
    current

    Proprietary real-world data points tied to clinical outcomes across multiple conditions, primarily from B2C operations.

    GLP-1 Program Launch
    —
    Q2 FY26

    Integrated program combining AI-powered engagement with licensed provider evaluation and access to FDA-approved GLP-1 therapies. Launched weeks after announcing provider-backed care strategy.

    Warrior Woman Program Launch
    —
    Q2 FY26

    Supports members navigating perimenopause and menopause, addressing associated weight changes, sleep disruption, and cardiometabolic risk.

    Carrier Sleep Program Launch
    —
    Q2 FY26

    Addresses obstructive sleep apnea, a significant contributor to cardiometabolic disease and rising healthcare costs.

    Industry KPIs

    2
    MetricValueDetails
    Healthcare client countmore than 180accounts
    Bookings billings growth$13.1MUSD

    Product announcements

    3
    ProductTypeDetails
    Integrated GLP-1 programlaunch
    Warrior Womanlaunch
    Carrier Sleeplaunch

    Deals & partnerships

    5
    Fortune 50 employerNew customer contract for diabetes and hypertension solutions.

    This is Dario's fifth Fortune 50 client.

    Major health insurer (via Amwell)Access to broader employer population through a single enterprise channel for cardiometabolic solution.

    Signed through channel partnership with Amwell.

    One of the five largest health insurers in the United StatesExpansion of existing relationship by adding hypertension program.

    Expanded from an existing behavioral health program. This is the third health plan customer to expand beyond an initial deployment.

    CeleraExtended hypertension program across the full spectrum of severity.

    Expansion through channel partnership.

    New channel partnerAdding a new channel partner with broad reach.

    Expected to cover employers, health plans, and health systems.

    Risks & headwinds

    2
    Near-term revenue decline from strategic transitionNear-term (Q2 FY26)

    Revenue for Q2 FY26 was $5.2 million, compared with $5.6 million in Q1 FY26 and $5.4 million in Q2 FY25.

    Mitigation: Strategic decision to prioritize higher quality recurring B2B2C revenue, which is expected to strengthen the long-term predictability of the business. Focus on operating efficiency and expense reduction.

    Delay in conversion of contracted ARR to recognized revenueH2 FY26 and FY27

    Contracted annual recurring revenue of $13.1 million takes typically 4-5 quarters from signature to full run-rate revenue.

    Mitigation: Management expects revenue to begin contributing in H2 2026, with the majority in 2027, as implementations mature and enrollment ramps.

    What to watch in Q3 FY26

    4

    Contracted ARR conversion to revenue

    H2 FY26
    Current$13.1M contracted ARR
    TargetInitial contribution to recognized revenue

    Why it matters

    Verifies the effectiveness of the commercial model and the transition to B2B2C recurring revenue.

    Applying that four to five quarter cycle, we expect to begin seeing this convert into revenue in the second half of this year, the majority of the contribution showing up in 2027 as implementations mature and enrollment ramps across the base.

    Q&A highlights

    4

    Can you provide more details on the sequential decline in B2B2C revenue and how to think about the magnitude of acceleration in the back half of the year?

    The revenue decline was due to strategic cleanup post-transformation and closing the pharma channel. The $13.1 million contracted ARR is expected to start converting in H2, gaining traction into Q1 next year. Efficiency gains mean new revenue will be highly accretive to the bottom line.

    “The slight decline is coming from additional cleanup that we did post all the transformation and after closing the pharma challenge. ... we think that in the second half, we're going to start to see this revenue starting to gain traction. you're going to see the growth between Q3 to Q4 with more momentum into Q1 of next year.”

    asked by Aidan Conniff · answered by Erez Rafael

    2 min read6 chapters

    Detailed Narrative

    01

    Compounding Growth Strategy

    Erez Rafael outlined four drivers of compounding growth: account depth (more revenue per existing customer), distribution efficiency (faster, cheaper customer acquisition), AI leverage (more revenue per member, lower cost to serve), and value chain participation (access to more healthcare spend). This strategy builds on a decade of platform development and clinical validation, positioning DarioHealth for future expansion and profitability.

    02

    Commercial Momentum & Channel Partners

    The company is seeing strong commercial execution, with over 180 signed accounts, including 5 Fortune 50 companies and approximately 25% of its B2B2C client base from the Fortune 500. Approximately 75% of new accounts now come through channel partners, leading to shorter sales cycles and lower customer acquisition costs, particularly for the small business market. Recent wins include a new Fortune 50 employer and a major health insurer signed via Amwell.

    03

    Multi-Condition Expansion

    Dario's multi-condition platform is driving growth within existing accounts. Nearly all new enterprise opportunities involve multiple conditions. A top-5 US health insurer expanded its relationship by adding hypertension to an existing behavioral health program, with potential to triple revenue. Over 80% of contracted and late-stage recurring revenue is now multi-condition, demonstrating the strategy's effectiveness in broadening eligible member populations and creating meaningful recurring revenue.

    04

    AI Leverage with DarioIQ

    DarioIQ, the proprietary AI agent trained on 13 billion data points from FDA-cleared devices, is central to the strategy. It delivers personalized clinical recommendations, improves member engagement and retention, and is expected to increase recurring revenues from existing customers by 10-15%. AI is also applied internally to reduce operating expenses, contributing to the company's expense discipline.

    05

    New Offerings & Provider-Backed Care

    The company rapidly launched an integrated GLP-1 program, combining its AI platform with licensed provider evaluation and access to therapies. This was possible due to existing infrastructure. Additionally, new programs like Warrior Woman (perimenopause/menopause) and Carrier Sleep (obstructive sleep apnea) were introduced, expected to contribute revenue in Q4 FY26, further expanding the platform's reach and monetization opportunities.

    06

    Financial Discipline & Balance Sheet Strength

    Despite a strategic revenue decline due to transitioning away from pharmaceutical services, DarioHealth improved its gross margin to 62% and reduced operating expenses by 21% year-over-year. Net loss improved by 39% to $7.9 million. A pro forma cash position of $36.8 million as of June 2026, bolstered by a July direct financing, provides a strong cash runway for future growth and path to cash flow positivity.

    AI-generated summary of the company’s earnings call. Not investment advice.